A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
08/06/2022at 09:02

Eli Lilly share price boosted by obesity data for diabetes treatment

The Eli Lilly share has performed better than the broad S&P 500 index so far this year. After positive obesity data was announced for tirzepatide on Tuesday, the share got another boost.
Photo: Mike Blake/REUTERS / X00030
by marketwire, translated by catherine brett

US-based Eli Lilly has had the wind in its sails on the stock market this week.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: MIKE SEGAR/REUTERS / X90033

    Eli Lilly squares up to Novo Nordisk on obesity market

    For subscribers

  • Photo: Zealand Pharma / PR

    Zealand Pharma obesity drug continues to phase II

    For subscribers

  • Photo: MIKE SEGAR/REUTERS / X90033

    Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Photo: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.
  • Novo Nordisk declared world's best place to work in 2022
  • Novo Nordisk meets upgraded guidance, sets new revenue record

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

For subscribers

Further reading

Foto: Tidsvilde Stine/Ritzau Scanpix
Pharma & biotech

Novo Nordisk declared world's best place to work in 2022

The Best Places to Work organization has released its 2022 list of the best workplaces across the world, and Danish Novo Nordisk shines at the top.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Analysis firm names two Novo Nordisk drugs in 2023 top sales growth prediction

Evaluate Vantage has come out with a list of predictions for the biggest 2023 growth engines when it comes to pharma products.

For subscribers

Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Eli Lilly predicts possible launch of obesity drug in 2023

The US-based company hopes to launch Wegovy-competitor tirzepatide for obesity this year or early next year.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Senior Clinical Project Manager

  • Application Manager

  • Commercial Director

  • Regulatory Affairs Professional

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Supply Chain Manager

See all jobs

Jobs

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Senior Clinical Project Manager

  • Application Manager

  • Commercial Director

  • Regulatory Affairs Professional

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Supply Chain Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge